Literature DB >> 21602551

Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models.

Zahoor Ahmad1, Mostafa M Fraig, Michael L Pinn, Sandeep Tyagi, Eric L Nuermberger, Jacques H Grosset, Petros C Karakousis.   

Abstract

OBJECTIVES: It is widely believed that persistent Mycobacterium tuberculosis inhabits necrotic lung granulomas in humans and that the microenvironmental conditions encountered therein render the bacilli phenotypically tolerant to antibiotics, accounting for the long duration required for successful treatment of tuberculosis (TB). To validate this belief, we directly compared the activity of rifampicin/isoniazid/pyrazinamide (RHZ) against chronic TB infection in guinea pigs, which exhibit caseous granulomas histologically resembling human caseous foci, and in mice, which lack necrotic granulomas.
METHODS: Guinea pigs and mice were aerosol-infected with M. tuberculosis CDC1551 and twice weekly treatment with RHZ was started 4 weeks later. Culture-positive relapse was assessed in subgroups of guinea pigs after 3 months and 4 months of treatment.
RESULTS: All guinea pig lungs exhibited histological evidence of granulomas with central caseation, while mouse lungs exhibited cellular lesions at the initiation of antibiotic treatment. Guinea pig lungs became culture-negative after 2 months of RHZ given twice weekly at human-equivalent doses. Relapse rates in guinea pigs were 0% (0/10) both after 3 months and 4 months of treatment. In contrast, all mouse lungs remained culture-positive after 4 months of equivalent RHZ exposures.
CONCLUSIONS: Caseous necrosis does not reduce the sterilizing activity of the standard antituberculosis regimen of RHZ. Our findings have important implications for the use of alternative animal models in testing novel TB drug regimens and for modelling M. tuberculosis persistence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21602551      PMCID: PMC3112031          DOI: 10.1093/jac/dkr188

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  32 in total

Review 1.  Disease model: pulmonary tuberculosis.

Authors:  D N McMurray
Journal:  Trends Mol Med       Date:  2001-03       Impact factor: 11.951

2.  Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts.

Authors:  R J REES; P D HART
Journal:  Br J Exp Pathol       Date:  1961-02

3.  The antituberculous activity of pyrazinamide in vitro and in the guinea pig.

Authors:  W STEENKEN; E WOLINSKY
Journal:  Am Rev Tuberc       Date:  1954-08

4.  Pyrazinamide (aldinamide) in experimental tuberculosis of the guinea pig.

Authors:  F I DESSAU; R L YEAGER; F J BURGER; J H WILLIAMS
Journal:  Am Rev Tuberc       Date:  1952-05

5.  Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis.

Authors:  Pere-Joan Cardona; Isabel Amat; Sergi Gordillo; Virginia Arcos; Evelyn Guirado; Jorge Díaz; Cristina Vilaplana; Gustavo Tapia; Vicenç Ausina
Journal:  Vaccine       Date:  2005-02-03       Impact factor: 3.641

6.  Postantibiotic effects of antituberculosis agents alone and in combination.

Authors:  C Y Chan; C Au-Yeang; W W Yew; M Hui; A F Cheng
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

7.  Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

Authors:  Anne J Lenaerts; Donald Hoff; Sahar Aly; Stefan Ehlers; Koen Andries; Luis Cantarero; Ian M Orme; Randall J Basaraba
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

9.  Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.

Authors:  Zahoor Ahmad; Lee G Klinkenberg; Michael L Pinn; Mostafa M Fraig; Charles A Peloquin; William R Bishai; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

10.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more
  14 in total

1.  Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.

Authors:  Rokeya Tasneen; Si-Yang Li; Charles A Peloquin; Dinesh Taylor; Kathy N Williams; Koen Andries; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

Authors:  Ciaran Skerry; Michael L Pinn; Natalie Bruiners; Richard Pine; Maria L Gennaro; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2014-05-22       Impact factor: 5.790

3.  Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Authors:  Kathy Williams; Austin Minkowski; Opokua Amoabeng; Charles A Peloquin; Dinesh Taylor; Koen Andries; Robert S Wallis; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

4.  Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Shaobin Shang; Crystal A Shanley; Megan L Caraway; Eileen A Orme; Marcela Henao-Tamayo; Laurel Hascall-Dove; David Ackart; Ian M Orme; Diane J Ordway; Randall J Basaraba
Journal:  Vaccine       Date:  2012-01-11       Impact factor: 3.641

5.  De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.

Authors:  Jees Sebastian; Sharmada Swaminath; Rashmi Ravindran Nair; Kishor Jakkala; Atul Pradhan; Parthasarathi Ajitkumar
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

6.  Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen.

Authors:  Noton K Dutta; Rongjun He; Michael L Pinn; Yantao He; Francis Burrows; Zhong-Yin Zhang; Petros C Karakousis
Journal:  ACS Infect Dis       Date:  2015-12-24       Impact factor: 5.084

7.  Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of Tuberculosis.

Authors:  Xiuhao Chen; Hiroyuki Hashizume; Tatsuo Tomishige; Izuru Nakamura; Miki Matsuba; Mamoru Fujiwara; Ryuki Kitamoto; Erina Hanaki; Yoshio Ohba; Makoto Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

8.  Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.

Authors:  Noton K Dutta; Peter B Illei; Charles A Peloquin; Michael L Pinn; Khisimuzi E Mdluli; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

9.  Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.

Authors:  Noton K Dutta; Abdullah Alsultan; Thomas J Gniadek; Deborah A Belchis; Michael L Pinn; Khisimuzi E Mdluli; Eric L Nuermberger; Charles A Peloquin; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

Review 10.  New insights into TB physiology suggest untapped therapeutic opportunities.

Authors:  Christina E Baer; Eric J Rubin; Christopher M Sassetti
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.